Researchers develop engineered blood clots for rapid haemostasis and enhanced tissue regeneration
Updated
Updated · Nature.com · Apr 29
Researchers develop engineered blood clots for rapid haemostasis and enhanced tissue regeneration
6 articles · Updated · Nature.com · Apr 29
Engineered blood clots (EBCs) form within seconds, increasing fracture toughness by 13-fold and adhesion energy by 4-fold compared to native clots.
In vivo studies show EBCs rapidly halt haemorrhage, promote tissue regeneration, reduce inflammation, and prevent postoperative adhesion, with both autologous and allogeneic EBCs validated for safety and efficacy.
Previous reports highlight that Jianyu Li's team at McGill University achieved clotting in rats in just 5 seconds, drastically reducing blood loss and outperforming existing haemostatic products, with potential applications in surgery and regenerative medicine.
When will the seemingly miraculous 'Click Clotting' technology actually begin its first human trials?
Could engineering blood cells to clot on demand create a hidden, deadly risk of thrombosis?
As gene therapies face market hurdles, is 'Click Clotting' the next big commercial success?
Can this rapid blood-clotting gel be practically prepared and used on a chaotic battlefield?
How does this injectable gel truly compare to emerging synthetic platelets or spray-on powders?
What are the unknown long-term effects of leaving these engineered cells inside the human body?